; Whereas additional awareness and research of APOL1 genetic mutations are needed to improve understanding of the kidney disease disparities in this population; Whereas there are currently no Food and Drug Administration-approved treatments available for APOL1-mediated kidney disease, but ongoing research and clinical trials could provide an opportunity for researchers to develop and test safe treatments for APOL1-mediated kidney disease; and Whereas the House of Representatives can raise public awareness of APOL1-mediated kidney disease: Now, therefore, be it